Indivior develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The Company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue and CNS disorders/schizophrenia. It markets and promotes Suboxone sublingual film, Suboxone sublingual tablet and Subutex sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex and Buprenex.

Company Growth (employees)
Slough, GB
Size (employees)
934 (est)+13%
Indivior is headquartered in Slough, GB

Indivior Office Locations

Indivior has offices in Slough, Richmond, Ottawa, Mannheim and in 11 other locations
Slough, GB (HQ)
105 Bath Rd
Beijing, CN
1 Dong San Huan Zhong Lu
Massy, FR
15 Rue Ampère
Milano, IT
7 Via Giovanni Spadolini
Mannheim, DE
3 Hermsheimer Str.
Ottawa, CA
2 Gurdwara Rd
Show all (15)

Indivior Data and Metrics

Indivior Financial Metrics

Indivior's revenue was reported to be £819.4 m in FY, 2016 which is a 18% increase from the previous period.

Revenue (FY, 2016)

819.4 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

736.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

27.1 m

Market capitalization (21-Sep-2017)

2.3 b

Closing share price (21-Sep-2017)


Cash (31-Dec-2016)

535.9 m
Indivior's current market capitalization is £2.3 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


799.6 m762.9 m693.8 m819.4 m

Revenue growth, %


Cost of goods sold

68.4 m65 m66.4 m82.9 m

Gross profit

731.2 m697.9 m627.4 m736.5 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016


4.6 m226.5 m361.7 m535.9 m

Accounts Receivable

111.1 m110.8 m130.9 m158.8 m

Current Assets

149.9 m386.6 m558.4 m766.7 m


121.7 m62.3 m119.3 m105.3 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

520.2 m301 m247.8 m315.2 m

Cash From Financing Activities

(530 m)(61.6 m)(111.5 m)(113.8 m)

Income Taxes Paid

(135.5 m)(108.1 m)(44.1 m)(48.8 m)
Y, 2016

Financial Leverage

-4.1 x
Show all financial metrics

Indivior Operating Metrics

Indivior's Clinical Programs was reported to be 12 in FY, 2016
FY, 2016

Phase III Trials


Clinical Programs


Phase I Trials


Phase II Trials

Show all operating metrics

Indivior Market Value History

Traffic Overview of Indivior

Indivior News and Updates

BRIEF-Indivior announces intention to list ADRs in U.S.

* Each american depositary share is expected to represent five indivior ordinary shares.

Indivior Company Life and Culture

You may also be interested in